Search research articles
Contact Us
Filters
Showing results (161-170 of 200) with videos related to
Page
of 20
Sort By:
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Journal for Immunotherapy of Cancer
|
January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
Vincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
JCO Precision Oncology
|
September 14, 2020
Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report
Ilana B Solomon, Sarah McGraw, Jenny Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal Cancer
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Journal of Gastrointestinal Oncology
|
August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A Fabrizio, Thomas J George, Richard F Dunne, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Ronan J Kelly, Katherine Bever, Joseph Chao, et al.
Annals of Surgical Oncology
|
August 13, 2021
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial
Mustafa Raoof, Gautam Malhotra, Adrian Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem, Sanne Huijberts, Axel Grothey, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 200) with videos related to
Sort By:
Page
of 20
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Journal for Immunotherapy of Cancer
|
January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
Vincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
JCO Precision Oncology
|
September 14, 2020
Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report
Ilana B Solomon, Sarah McGraw, Jenny Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal Cancer
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
Journal of Gastrointestinal Oncology
|
August 29, 2018
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A Fabrizio, Thomas J George, Richard F Dunne, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Ronan J Kelly, Katherine Bever, Joseph Chao, et al.
Annals of Surgical Oncology
|
August 13, 2021
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial
Mustafa Raoof, Gautam Malhotra, Adrian Kohut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem, Sanne Huijberts, Axel Grothey, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
Page
of 20